Trends in the treatment of dermatophytosis

Revista Iberoamericana de Micologia

Volumn 17, Issue SUPPL., 2000, Pages 148-158

  Del Palacio, A ^a   Garau, M ^a   Gonzalez Escalada, A ^a   Calvo, M T ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Dermatophytosis; Systemic treatment; Topical treatment

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL ACTIVITY; ARTICLE; DERMATOPHYTE; HUMAN; NONHUMAN; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0033819951     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. Guidelines for the diagnosis, prevention and control of dermatophytosis in man and animals
2. The superficial mycoses and the dermatophytes
3. Epidemiology of ringworm (dermatophytosis)
4. Geographic distribution of the dermatophytes: A review
5. Experimental ringworm of guinea pigs: Oral treatment with griseofulvin
6. Griseofulvin: A new look at an old drug
7. Antifungal agents: An overview. Part I
8. The role of sweat in the pharmacokinetics of ketoconazole and griseofulvin
9. Hepatic injury associated with ketoconazole therapy: Analysis of 33 cases
10. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections
11. Treatment and prophylaxis of tinea infections
12. Antifungal agents: An overview. Part II
13. Pharmacokinetic profile of orally administered itraconazole in human skin
14. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients
15. In vitro studies of activity of voriconazole (UK-109496) a new triazole antifungal agent, against emerging and less common mold pathogens
16. Potencial new antifungal agents
17. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin
18. Terbinafine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses
19. Pharmacokinetics and pharmacology of terbinafine and itraconazole
20. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks
21. Adverse drug reactions of the new oral antifungal agents-terbinafine, fluconazole and itraconazole
22. Cutaneous adverse effects associated with terbinafine therapy: 10 Case reports and a review of the literature
23. Persistent impairment of taste resulting from terbinafine
24. Terbinafine-induced lupus erythematosus
25. Hepatitis associated with terbinafine therapy: Three case reports and the review of the literature
26. Thrombocytopenia associated with oral terbinafine
27. The development of green vision in association with terbinafine therapy
28. Clinical pearl: Antifungal drugs and drug interactions
29. Risk/benefit ratio of modern antifungal therapy: Focus on hepatic reactions
30. Cost of therapy for dermatophyte infections
31. Topical (1%) solution of griseofulvin in the treatment of tinea corporis
32. Anti-inflammatory activity of antifungal preparations
33. Overview of topical therapy for common superficial fungal infections and the role of new topical agents
34. Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream
35. One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: A multicenter, double-blind trial
36. Butenafine 1% cream in the treatment of tinea cruris: A multicenter, vehicle controlled, double-blind trial
37. Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis
38. The envolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis
39. First Symposium on Terbinafine
40. Overview of the use of terbinafine (Lamisil) in children
41. Terbinafine (Lamisil) therapy for Microsporum canis scalp ringworm
42. Efficacy of terbinafine treatment of tinea capitis varies according to the dermatophyte species
43. Therapeutic efficacy of terbinafine in the treatment of three children with tinea tonsurans
44. Systemic antifungal treatment of children with terbinafine
45. In vitro activity of terbinafine
46. The problem in tinea capitis control in a home for mentally handicapped children
47. Randomized single-blind study of efficacy and tolerability of terbinafine in the treatment of tinea capitis
48. Tinea capitis
49. Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species
50. Itraconazole versus griseofulvin in the treatment of tinea capitis: A double-blind randomized study in children
51. Treatment of tinea capitis with itraconazole
52. Itraconazole pulse therapy for tinea capitis: A novel treatment schedule
53. Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: An open multicenter study
54. Terbinafine pulse therapy is effective in tinea capitis
55. Fluconazole for the treatment of tinea capitis in children
56. Tinea capitis: Fluconazole in Trichophyton tonsurans infection
57. A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis
58. Therapy and management of ringworm infections
59. Tinea capitis in South East London - A new pattern of infection with public health implications
60. Prevalence of undetected tinea capitis in a school survey in Spain
61. Prevalence of undetected tinea capitis in a prospective school survey in Madrid: Emergence of new causative fungi
62. Tinea capitis: Recommendations for school attendance
63. Treatment of symptom-free carriers in management of tinea capitis
64. Onychomycosis. Agents of choice
65. Avances en el tratamiento de onicomicosis y dermatofitosis
66. Tratamiento antifungico: Ultimos avances en dermatologia
67. Partial surgical avulsion of the nail in onychomycosis
68. Onychomycosis: Experience with non-traumatic nail avulsion
69. Urea ointment in non-surgical avulsion of nail dystrophies, reappraisal
70. Combination urea and salicylic acid ointment nail avulsion in one dystrophic nail: Follow-up observation
71. Is tinea unguium still widely incurable?
72. Subungueal dermatophytoma complicating dermatophyte onychomycosis
73. Long term results of patients with onychomycosis treated with itraconazole
74. Oral terbinafine in toe nail dermatophytosis. A double-blind, placebo controlled multicenter study with 12 months follow-up
75. Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: A pharmacokinetic comparison
76. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany
77. Oral treatment schedules for onychomycosis: A study of patient preference
78. A 12-week treatment for dermatophyte toe onychomycosis: Terbinafine 250 mg/day vs itraconazole 200 mg/day - A double-blind comparative trial
79. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis
80. Double-blind randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis
81. Pharmacokinetics of three doses of once weekly fluconazole (150, 300 and 450 mg) in distal subungueal onychomycosis of the toenail
82. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungueal onychomycosis of the fingernail
83. Once-weekly fluconazole (150, 300 or 450 mg) in the treatment of distal subungueal onychomycosis
84. Once weekly fluconazole (450 mg) for 4, 6 or 9 months of treatment for distal subungueal onychomycosis of the toenail
85. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails
86. A randomized comparative study: Amorolfine (cream 0.125, 0.25 and 0.5) in dermatomycoses
87. A clinical double-blind trial comparing amorolfine cream 0.5% (RO-14-4767) with bifonazole cream 1% in the treatment of dermatomycoses
88. Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: A phase II dose-finding pilot study
89. A double-blind, randomized comparative trial: Flutrimazole 1% solution versus bifonazole 1% solution once daily in dermatomycoses
90. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris
91. Estudio doble ciego randomizado comparativo con itraconazol y griseofulvina en tinea corporis y tinea cruris
92. Estudio doble ciego aleatorio comparativo con itraconazol y griseofulvina en tinea manuum y tinea pedis
93. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris
94. A comparison of the efficacy of oral fluconazole, 150 mg/day versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis and cutaneous candidosis
95. The antibacterial efficacy of econazole in interdigital toe web infections
96. Interdigital athlete's foot: The interaction of dermatophytes and resident bacteria
97. The clinical efficacy of terbinafine in the treatment of fungal infections of the skin
98. Chronic ringworm infection of the skin and nails treated with griseofulvin. Report of a therapeutic trial
99. Comparison of ketoconazole and griseofulvin in the treatment of tinea pedis
100. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): A double blind multicentre study
101. Chronic dermatophyte infections. I: Clinical and mycological features
102. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 100 mg/day in plantar-type tinea pedis
103. Itraconazole for the treatment of tinea pedis: A dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks
104. Short term itraconazole versus terbinafine in the treatment of tinea pedis or manus
105. Efficacy of oral fluconazole in tinea pedis of the hyperkeratotic type. Stratum corneum levels